



CIO expects strong growth for the healthcare sector. (UBS)

UBS CIO upgrades healthcare to Most Preferred

13 March 2024, 7:54 pm CET, written by UBS Editorial Team

This month, the UBS Chief Investment Office (CIO) thinks the backdrop for US equities remains supportive driven by healthy economic growth, moderating inflation, a Fed that's pivoting to rate cuts, and a strong surge in AI investment. Healthcare in particular has seen faster earnings growth relative to the other defensive sectors, which is why CIO has upgraded it from Neutral to Most Preferred.

Eric Potoker, US Healthcare Equity Strategist with CIO, spoke with UBS On-Air's Dan Cassidy to explain the reasoning behind upgrade. [Click here](#) to listen to his commentary and read highlights below:

The equity strategy team views healthcare as the most attractive among the defensive sub-sectors, and overall that Most Preferred view of healthcare serves to balance other Most Preferred sectors, which are the pro-cyclicals technology and industrials. Specific to healthcare, we've seen a general improvement of the sector end markets through 2023 and an acceleration of earnings growth through the sector broadly.

Unlike last year, there is little in the way of a "post-pandemic hangover" to slow growth in 2024. In 2023, there were a number of large companies that saw growth slow, or even go negative, because they were no longer benefiting from the same magnitude of COVID tailwinds. That's been normalized for 2024, which allows the healthcare sector to generate faster earnings growth on both an absolute and relative basis.

CIO has three preferred sub-sectors of US healthcare.

1. **Medtech/medical devices.** This continues to be a structurally strong end-market, and this year we expect to see even better growth and a lot of that is procedure volumes, some of which is pent-up post-pandemic demand, and

some of it is due to new products that are coming to market and adding to growth. We think this sub-sector will continue to show strong growth and think certain parts of the sector will accelerate in 2024 and beyond.

- 2. Life sciences tools.** This sector in particular suffered from a COVID-19 hangover in 2023 and should benefit from a normalization of what we see in recovering end-markets. The sector struggled last year with weakness in small-cap biotech funding availability and large biopharma companies bringing down their inventory levels from pandemic peaks. We think the inventory correction is mostly finished and there has been a decent recovery so far this year in biotech access to capital.
- 3. Managed care sector.** This group has struggled due to higher medical utilization, which we do think is transitory in terms of how it will impact margins. We also think that by the second half of the year, some of that pressure will moderate and that these companies will be able to show margins and earnings that are consistent with guidance. Given where valuations are, we think MCOs are at an attractive entry point for managed care.

CIO is still Neutral on large bio-pharma. Obesity drug therapies dominate pharma. There's a significant divergence of valuations within the sector between the "haves" and the "have nots" that centers on obesity drugs, and there are only a couple of players with an effective, marketed obesity drug. While there are some attractive valuations that represent value, CIO sees looming pressure from many large products losing patent protection over next three years.

Take a deeper dive:

- Read the report [CIO View: US equity sectors](#) 22 February 2024.
- Listen to the podcast [US healthcare—Sector update and outlook](#) 13 March 2024.

Disclaimer

This document is prepared and published by the Global Wealth Management business of UBS Switzerland AG (regulated by FINMA in Switzerland), its subsidiaries or its affiliates ("UBS"), part of UBS Group AG ("UBS Group"). UBS Group includes Credit Suisse AG, its subsidiaries, branches and affiliates. In the USA, UBS Financial Services Inc. is a subsidiary of UBS AG and a member of FINRA/SIPC. This document and the information contained herein are provided solely for your information and UBS marketing purposes. Nothing in this document constitutes investment research, investment advice, a sales prospectus, or an offer or solicitation to engage in any investment activities. This document is not a recommendation to buy or sell any security, investment instrument, or product, and does not recommend any specific investment program or service.

Information contained in this document has not been tailored to the specific investment objectives, personal and financial circumstances, or particular needs of any individual client. Certain investments referred to in this document may not be suitable or appropriate for all investors. In addition, certain services and products referred to in the document may be subject to legal restrictions and/or license or permission requirements and cannot therefore be offered worldwide on an unrestricted basis. No offer of any product will be made in any jurisdiction in which the offer, solicitation, or sale is not permitted, or to any person to whom it is unlawful to make such offer, solicitation, or sale.

Although all information and opinions expressed in this document were obtained in good faith from sources believed to be reliable, no representation or warranty, express or implied, is made as to the document's accuracy, sufficiency, completeness or reliability. All information and opinions expressed in this document are subject to change without notice and may differ from opinions expressed by other business areas or divisions of UBS Group. UBS is under no obligation to update or keep current the information contained herein. **The views and opinions expressed in this material by third parties are not those of UBS.** Accordingly, UBS does not accept any liability over the content shared by third parties or any claims, losses or damages arising from the use or reliance of all or any part thereof. All pictures or images ("images") herein are for illustrative, informative or documentary purposes only and may depict objects or elements which are protected by third party copyright, trademarks and other intellectual property rights. Unless expressly stated, no relationship, association, sponsorship or endorsement is suggested or implied between UBS and these third parties.

Any charts and scenarios contained in the document are for illustrative purposes only. Some charts and/or performance figures may not be based on complete 12-month periods which may reduce their comparability and significance. Historical performance is no guarantee for, and is not an indication of future performance.

Nothing in this document constitutes legal or tax advice. UBS and its employees do not provide legal or tax advice. This document may not be redistributed or reproduced in whole or in part without the prior written permission of UBS. To the extent permitted by the law, neither UBS, nor any of its directors, officers, employees or agents accepts or assumes any liability, responsibility or duty of care for any consequences, including any loss or damage, of you or anyone else acting, or refraining to act, in reliance on the information contained in this document or for any decision based on it.

Additional Disclaimer relevant to Credit Suisse Wealth Management

This document is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject Credit Suisse to any registration or licensing requirement within such jurisdiction. Your personal data will be processed in accordance with the Credit Suisse privacy statement accessible at your domicile through the official Credit Suisse website <https://www.credit-suisse.com>. In order to provide you with marketing materials concerning our products and services, UBS Group AG and its subsidiaries may process your basic personal data (i.e. contact details such as name, e-mail address) until you notify us that you no longer wish to receive them. You can optout from receiving these materials at any time by informing your Relationship Manager.

Except as otherwise specified herein and/or depending on the local Credit Suisse entity from which you are receiving this report, this report is distributed by Credit Suisse AG, authorised and regulated by the Swiss Financial Market Supervisory Authority (FINMA). Credit Suisse AG is a UBS Group company.

Please visit [<https://www.ubs.com/global/en/wealth-management/insights/chief-investment-office/marketing-material-disclaimer.html>] to read the full legal disclaimer applicable to this material.

© UBS 2024. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.